$695 | Single User
$2850 | Site License
$5650 | Global License

Trends and Innovations in Companion Diagnostics
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Apr 2016 | 328 | In Stock
Related Topics: AstraZeneca , Business , Healthcare , Office , Personal , Reimbursement , Technology

Introduction

Introduction


Are companion diagnostics becoming a “must have” for market access?


Companion Diagnostics (CDx) are playing an increasingly vital role in market access by supporting product value claims and improving patient outcomes. What are the upsides for developers, pharma, payers and physicians and how can the challenges around new technology adoption, reimbursement and clinician uptake be overcome?


To really understand the issues and trends that are shaping the CDx market, senior managers in diagnostic development companies and the pharma industry should turn to this report.


“Pharma companies around the world are scouring tumour cells to find something different. It’s logical that detecting those differences would in fact then be down to a companion diagnostic.” Rob Steitz, Insight Genetics Inc.


Puchase Reasons


Answering key questions:


  • Pharma’s benefit: Are CDx becoming essential for regulatory approval and clinical diagnosis?

  • New therapy areas: Beyond oncology, what therapy areas are being targeted by CDx?

  • All in the timing: At what stage should CDx be included in a drug’s development?

  • New technologies: How revolutionary will next generation sequencing, liquid tumour testing, biopsies and bioinformatics be in driving future uptake of CDx?

  • Engaging Physicians: Many physicians do not use approved CDx, or choose alternatives. Should the use of approved CDx be mandatory and enforced?

  • Where’s the money? Reimbursement models do not reflect the wider value of advanced CDx – what are the options for change and how is this influencing developers thinking and investment?

  • Point of Care: What are the future prospects for the development of PoC CDx?

  • With this report you will be able to:


  • Identify the new CDx approaches and evaluate their benefits.

  • Understand how and where they will impact the market and review the challenges they must overcome.

  • Assess the activities, policies and partnerships of CDx-progressive pharma companies.

  • Understand how financial and reimbursement models need to change to reflect the real value of CDx.

  • Learn how advanced CDx can radically improve clinical trial research and outcomes.

  • Formulate strategies that encourage physicians to use approved CDx.

  • Identify the therapy areas and conditions where next generation CDx will make an impact.

  • Grasp the growing importance of research consortia in the identification of biomarkers.

  • Key Topics Explored:


  • Pharma is sometimes compelled to identify a CDx as part of securing regulatory approval, but physicians are not obligated to use it. Is it time to make their use mandatory?

  • Reimbursement models do not allow for premium pricing of advanced CDx. Taking potential cost savings and improved patient outcomes into account, isn’t it time that a fair price was paid?

  • Some pharma companies may see CDx as unnecessary revenue capping, while others take a more progressive view. Will the benefits of CDx mean they become key in supporting value claims and securing market access?

  • Pharmaceutical companies, diagnostic companies, patients, physicians, payers, testing laboratories and regulators are all stakeholders. They should be engaged as early as possible.

  • Payers have most to benefit by using CDx to ensure that expensive drugs are prescribed optimally, so why are some payers concerned?

  • Expert Contributors


  • Frank Apostel, VP Companion Diagnostics, R-Biopharm AG, Germany

  • Joachim Reischl, VP Head of Policy, Portfolio and Externalisation, Personalised Healthcare, AstraZeneca, EU

  • Richard Watts, Vice President, Companion Diagnostic Partnerships, Global Business Development, QIAGEN, USA

  • Rob Seitz, Chief Technology Officer, Insight Genetics Inc., USA

  • William Pignato, Regulatory Affairs Consultant, Companion Diagnostic, USA

  • Director, CDx Development, Japanese Pharma Company

  • Director, Corporate Development, European Diagnostic Company

  • Companion Diagnostic Expert, Global Diagnostic Company

  • Companion Diagnostic Expert, Specialist Diagnostic Company

  • All respondents met FirstWord’s stringent screening criteria, and were compensated for participating. To encourage frank and forthright responses, their names have been withheld.


    About FirstWord


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


    FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.


    FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

    Table of Contents
    for Trends and Innovations in Companion Diagnostics

    • 1 Executive Summary

      2 Research Objectives

      2.1 Research Methodology

      2.2 Definitions

      3 Setting the scene

      4 Clinical and economic benefits of developing a companion diagnostic

      5 Recent innovations in precision medicine and companion diagnostics

      6 Recent technological innovations in companion diagnostics

      7 Drivers and inhibitors for the uptake of CDx

      8 Factors influencing successful/unsuccessful partnerships

      9 Optimal and sub-optimal practice for developing companion diagnostics

      10 Regulatory impact on the development and uptake of CDx

      11 Managing stakeholder expectations on CDx programmes

      12 What needs to be done to encourage future innovation in CDx development?

      13 Future opportunities in CDx and precision medicines

      14 Appendix

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    328 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Drug Delivery - Innovations, trends, and their impact on pharma
    IntroductionWhy you need Drug Delivery - Innovations, trends, and their impact on pharmaRevolutionar...
    01 Nov 2015 by FirstWord Pharma USD $2,195 More Info
    Trends and Innovations in Key Account Management
    IntroductionYour customers need and demand more from you today. Key Account Management (KAM) is the ...
    01 Jul 2015 by FirstWord Pharma USD $695 More Info
    Physician Views: Assessing new competitive trends in the oral anticoagulant market
    ScopeThe new class of oral anticoagulants – comprising the Factor Xa inhibitors Xarelto (Bayer/Johns...
    01 Jun 2015 by FirstWord Pharma USD $695 More Info
    Trends & Innovations Sales Force Effectiveness
    IntroductionWhat makes an ideal modern pharma sales representative and what skills, knowledge, tools...
    01 Apr 2015 by FirstWord Pharma USD $695 More Info
    Trends and Innovations in Patient Adherence
    IntroductionTaking the right dose of the right medicine at the right time is key to improving health...
    01 Mar 2015 by FirstWord Pharma USD $695 More Info
    Trends and Innovations in Lifecycle Management
    IntroductionTrends and Innovations in Lifecycle Management (LCM) presents business-critical insights...
    01 Feb 2015 by FirstWord Pharma USD $695 More Info
    Trends and Innovations in Drug Pricing
    IntroductionFirstWord’s Trends and Innovations in Drug Pricing report dissects international trends ...
    01 Jan 2015 by FirstWord Pharma USD $695 More Info
    Trends in Measuring and Rewarding KAM Team Performance
    IntroductionKey account managers (KAMs) are the new face of pharma sales. Whether meeting with hospi...
    24 Nov 2014 by FirstWord Pharma USD $695 More Info
    Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification
    IntroductionIn 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative re...
    01 Dec 2012 by FirstWord Pharma USD $7,900 More Info
    Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis
    IntroductionPublic healthcare costs are rising. Governments need to get them under control. In Europ...
    01 Jan 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Trends and Innovations in Companion Diagnostics | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...